Voxvoganan is under clinical development by Pharma Holdings and currently in Phase II for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections. According to GlobalData, Phase II drugs for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Voxvoganan LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Voxvoganan overview

LTX-109 (Lytixar) is under development for the treatment of methicillin-susceptible staphylococcus aureus (MSSA) infections. It is administered topically and through nasal route as gel. LTX-109 is a synthetic antimicrobial peptide that targets cell membrane of pathogen.

It was also under development for impetigo, diabetic foot ulcers, gram-positive skin infections, vancomycin-resistant Enterococci (VRE) infections, hidradenitis suppurativa, coronavirus disease 2019 (COVID-19), nasal decolonization of MRSA(methicillin-resistant Staphylococcus aureus), eradication of staphylococcus aureus from the nose, impetigo and multi-resistant Pseudomonas aeruginosa infections

Pharma Holdings overview

Pharma Holdings develops drugs for the treatment of microbial infections. It operates in the research and development industry. The organization offers drugs with a lead compound which is an investigational antimicrobial medication with an original film lysing system of activity, given the natural standard of inborn resistant effectors, lytic peptides. Pharma Holding’s compound LTX-109 is derived from a normally happening peptide which, along with the low drive towards resistance improvement, guarantees a feasible approach to fending off diseases. It operates in Norway. Pharma Holdings is headquartered in Tromso, Finnmark, Norway.

For a complete picture of Voxvoganan’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.